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1. Introduction   
Infertility can arise as a consequence of treatment of oncological conditions. (5) The parallel 
and continued improvement in both, the management of oncology and fertility cases in 
recent times, has brought to the fore-front the potential for fertility preservation in patients 
being treated for cancer. (26)(27) 
Clearly Oncologists must be aware of situations where their treatment wills affect fertility in 
patients who are being treated for cancer and they must also be aware of the pathways 
available for procedures such as cryopreservation of gametes and/or embryos. (6) 
This surge in activity is based largely on the improved survival of women and girls from 
malignant disease. This has been particularly so in paediatric oncology, with a 
transformation from very low success rates for many conditions to the current situation 
where 80-90% of children with cancer can expect to survive long term. (1) 
The loss of fertility is a common consequence of the use of many therapeutic agents for non-
malignant as well as malignant conditions, including systemic lupus erythematosis and 
other rheumatological diseases. Bone marrow stem cell transplantation with chemotherapy 
conditioning is now being used in many other conditions.  
Some people are at risk for impaired fertility or infertility because of exposure to 
occupational or environmental hazards and thus might want to take measures to preserve 
their fertility. For example, some industries, particularly textiles, clinical laboratories, 
manufacturing, printing, and dry cleaning, frequently involve exposure to chemical 
hazards. Health-care workers can receive significant exposures to gonadotoxic agents such 
as estrogenic compounds, anesthetic gases, and chemotherapeutics, or compounds that can 
exert embryotoxic, teratogenic, or carcinogenic effects on the zygote, embryo, or fetus. 
Exposure to biologic agents (e.g., cytomegalovirus, hepatitis B virus, human 
immunodeficiency virus, human parvovirus B19, Listeria monocytogenes, rubella virus, or 
varicella/herpes zoster virus) also exposes risks to reproductive health. Also military 
personnel might want to take measures to preserve their fertility due to a risk of exposure to 
radiation, biologic, or chemical agents that can compromise their fertility. Furthermore, 
some individuals live in communities that could disproportionately expose them to 
pesticides, lead, and other toxins. 
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Female cancer patients between the ages of fifteen and forty-nine years are expected to not 
only survive their disease but also lead normal lives, mainly because of newer, more 
effective cancer therapies such as sterilizing chemotherapy and/or radiotherapy. (3) 
Consequently, fertility preservation has become an important quality-of-life issue. Problems 
with fertility and obstetric disorders such as early pregnancy loss, premature labor, and low 
birth weight have all been described after cancer treatment. (1) 
There is a range of alternative options to preserve fertility, based on the type and timing of 
chemotherapy, the type of cancer, the patient’s age and the partner status. 
Fertility preservation should be an integral part of improving the quality of life in cancer 
survivors. However it is neither possible nor ethical to recommend the same recipe for every 
cancer patient. 
2. The impact of oncology therapy on fertility 
2.1 Surgical management 
Surgery can impact on fertility. It can either render someone infertile by removal of 
reproductive organs or it can be affected by complications of surgery.  There is no doubt, 
however, that in recent years there has been a tendency towards more conservative 
treatment for many malignancies affecting the reproductive organs.(16) 
In women, there has been tendency towards less radical approaches to cervical cancer with 
the development of loop excision techniques for premalignant cervix lesions or in situ 
carcinoma and more recently the development of the radical abdominal and vaginal 
trachelectomy indicated in cervical cancer lesions stage I less than 2 cm (fig. 1), which allows 
a radical approach to cervix cancer that is treatable surgically, but with preservation of the 
uterus and thus fertility. (28)(22) 
Endometrial cancer is usually a disease of the postmenopausal group or at least in those 
who have had completed their family, and therefore it’s unusual for treatment of this 
disease, which does involve hysterectomy and bilateral oophorectomy, to impact upon 
fertility.  Today exist the possibility to detect early stage well-differentiated tumors that can 
be treated with resection of the lesion and progestin therapy. (29) 
Epithelial ovarian cancer continues to be treated radically with loss of reproductive 
organs. But increasing understanding of germ cell malignancies, borderline tumours of 
the ovary and epithelial tumors at stage IA grade I, has led to a more conservative 
approach to these neoplasms and often a single oophorectomy will be performed where in 
the past, a hysterectomy and/or bilateral oophorectomy would have been the treatment of 
choice. (10) 
It is unusual for vulvar carcinoma to be seen in the reproductive age group, and although it 
may have major psychosexual impact is unusual that surgical treatment impact upon 
fertility. In the case of early-stage vulvar cancer,  the radical excision of the lesion  and 
removing and examining one or two sentinel nodes in the groin and upper leg is an effective 
way to detect whether cancer has spread, but also results in fewer adverse side effects with 
great results and without being a posible cause of  infertility. (10) 
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Fig. 1. Radical Abdominal Trachelectomy for cancer of the cervix. A-B-C-D surgery stages. 
2.2 Effects of chemotherapy and radiotherapy 
With the improved survival rate of childhood and young adult cancer patients, the long-
term sequelae of the treatments used are increasingly important. Current knowledge of the 
gonadotoxicity of commonly employed chemotherapeutic agents and radiotherapy 
regimens is needed to differenciate  between the effect of "high-risk" and "low-risk" agents  
tailoring treatment to suit the individual and counseling patients regarding reduced fertility 
have resulted in the best practice. 
2.2.1 Chemotherapy 
Chemotherapy can produce significant effects upon patient fertility. (27)(26) These effects 
are dependent on a number of factors: 
• Radical versus adjuvant chemotherapy. Radical chemotherapy generally has more 
profound effects on fertility than adjuvant chemotherapy, 
• Single agent versus combination chemotherapy. Increasing complexities of regimes are 
more likely to have impacts upon fertility than single agent, 
• Dose-dependent effects. Increasing doses are likely to have more profound effects on 
fertility than lower doses, 
• Drug-dependent effects. Different agents have a markedly different impact upon 
fertility with some chemo-therapeutic agents sparing fertility while others are extremely 
toxic in this regard, 
• Age-dependent effects. In the female in particular, age has a profound effect on 
chemotherapy toxicity. 
Chemotherapy regimens administered to women under the age of 40 have a much higher 
chance of regaining the normal ovarian function whilst the majority of women over 40, 
administered toxic chemotherapy will be rendered menopausal by their treatment. 
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Presumably part of the reason for this is the fact that the natural attrition rate of oocyte sees 
a large drop in oocyte numbers over age 40 (decreased ovarian reserve) and this 
corresponds with decreased live birth rates in fertility patients over the age of 40. 
Detailed information regarding fertility effects of many chemotherapy regimes is lacking, 
but specific examples where chemotherapy affects fertility is documented include the 
following. 
Toxic effects of commonly used chemotherapeutic agents 
A fixed number of primordial follicles present at birth form the ovarian reserve into 
puberty. Postpuberty these primordial follicles contain single oocytes arrested in the 
prophase of the first meiotic division and are highly sensitive to cytotoxic drugs leading to 
cellular death. 
Follicular depletion has been shown to be physiologically age dependent, the maximum rate 
of depletion occurring around the age of 38 years when the reserve is just about 10% the 
number present at menarche. The gonadal toxic effect is thus not just dependent on type(s) 
and dosage of the cytotoxic drug(s) employed but also on the age of the woman.  
Cell cycle nonspecific agents such as cyclophosphamide (alkylating agent) are very 
gonadotoxic because they destroy resting primordial cells as opposed to cell cycle specific 
agents such as methotrexate (antimetabolite) and Antibiotics which spare the rest 
primordial cells and, as such, are less gonadotoxic. 
The toxicity of chemotherapy on the ovary depends on the type of drug, the mechanism of 
action and the age of the patient. Alkylating agents are among the most gonadotoxic, and 
cyclophosphamide remain the most important since it is widely used in therapeutic 
regimens, especially for breast cancer. The dose of cyclophosphamide that leads to ovarian 
failure is age dependent, since for example requires 20.4 g for a patient aged 20 to 29 years to 
start with amenorrhea while for a patient over 40 years only takes 5.5 grams of cumulative 
dose to a total ovarian failure. Moreover, there are drugs with minimal gonadotoxic effects 
as antimetabolites (methotrexate and fluorouracil), alkaloids (vincristine or  etopocide) and 
antibiotics (actinomycin-D, doxorubicin and bleomycin). The patients treated for gestational 
throfoblastic disease and ovarian tumors of germ line, that use this type of drugs have low 
gonatotoxic effect preserving the possibility of future fertility. 
So we can conclude based on what we observed that: 
i. Adriamycin and cyclophosphamide have a 38% ovarian failure rate in women aged 
over 40 years at 2 years post chemotherapy. 
ii. Cyclophosphamide, Hydroxydaunorubicin (Adriamycin) Oncovin (vincristine), and 
Prednisolone do not usually lead to permanent amenorrhoea in women under 40 years 
of age, but may lead to early menopause in older women. 
iii. ABVD (Doxorubicin, Bleomycin, Vinblastin, and Dacarbazine) used in the treatment of 
Hodgkin’s disease is significantly less toxic in terms of fertility than the older MOPP 
(Mechlorethamine, Vincristine, Procarbazine and Prednisolone). 
iv. Bleomycin and doxorubicin have minimal effects on fertility. 
v. Vinca alkaloids and antimetabolites have very mild effects on fertility (Methotrexate 
very mild at 6 gm total dose). 
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vi. Taxanes are not clearly defined in terms of their impact on fertility. 
vii. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) a classical breast cancer 
regime will render 71% of women over 40 years of age amenorrhoeic at 2 years.(25)(24) 
2.2.2 Radiotherapy  
The principle of radiotherapy is based on the ionisation of cellular atoms and molecules 
leading to the destruction of double and single DNA structures within the cell structure. 
A chain of events is set up, disrupting the cell-cycle leading to apoptosis of the cells. 
Radiotherapy has its use in oncology because unlike malignant cells, most normal cells have 
the inert ability to recover from the effects of radiotherapy. 
Clearly radiotherapy can be administered as external beam therapy (teletherapy), or as 
intracavity (brachytherapy) treatments. In addition to this, radiotherapy can be given with 
radical curative intent or as adjuvant therapy often postoperatively. 
The direct effects of radiotherapy are dose dependent and are also dependent on the field 
applied to the individual. It is important to consider the effect of scattered radiation as well 
as direct irradiation when assessing likely effects on fertility. (25) 
The application of 14.3 Gray to an ovary in a woman over 30 years of age will usually render 
her irreversibly infertile and menopausal. A dose of 6 Gray to the ovary of a woman less than 
30 years of age is usually reversible, but ultimately, will bring the menopause forwards. 
Thus the female is not only concerned with issues regarding fertility but also with hormone 
production, as both seem to be equally affected by radiotherapy. 
Although the uterus is relatively resistant to radiotherapy there is no doubt that uterine 
irradiation is harmful and even if fertility is conserved, uterine irradiation will result in poor 
implantation. This appears to be due to a number of factors including reduced uterine 
volume and blood flow which have been demonstrated to result in increased mid-trimester 
losses, preterm labour and intrauterine growth retardation. (1) 
The vagina is relatively radio-resistant however; irradiation of this organ carries with it the 
risk of loss of lubrication and stenosis which may result in physical impairments to fertility 
as well as major psychosexual issues. (1) 
3. Options for fertility preservation  
As illustrated in Figure 2, there is a range of clinical scenarios in which different fertility 
preservation techniques are appropriate. These can be discussed with the patient or, in the 
case of a child, with the patient and her parents. (8) 
The American Society of Clinical Oncology (ASCO), the American Society for Reproductive 
Medicine and the NICE guidance recommend that all such patients of childbearing age be 
informed about fertility preservation treatment options. Despite these recommendations 
and the expanding availability of fertility preservation services, surveys of oncologists have 
revealed that only a small minority of eligible patients are referred to reproductive 
endocrinologist for fertility preservation counselling. (17)(18) 
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Current fertility preservation treatment options include emergency embryo an oocyte 
cryopreservation and ovarian tissue freezing.  
The most successful alternative for female survivors is embryo cryopreservation, which is 
available in all IVF units ( In Vitro Fertilization), an approach not suitable for many single 
women or even possible for prepuberal girls.  
Preserving fertility through the cryopreservation of ovarian tissues or oocytes (although still 
in experimental stages) would increase the chances that children or single women could 
someday become parents even after exposure to chemotherapy or other agents that can 
cause infertility.  (9)(11) 
When there is ovarian involvement, or when potential for occult metastasis is high, 
however, ovarian tissue should not be cryopreserved for the purpose of autotransplantation. 
In theory, normal appearing ovarian tissue can be cryopreserved with the idea of future in 
vitro maturation of primordial follicles and xenografting. (12) 
Preventing reproductive failure would be an ideal approach. Research is under way to 
evaluate treatment with gonadotropin-realising hormones (GnRh) in conjunction with 
chemotherapy, inducing a transient prepubertal state that might reduce the damage to 
reproductive organs and thereby prevent oocyte death during cancer treatment.  
 
Fig. 2. Fertility Preservation options. 
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However, fertility preservation using ovarian suppression with GnRh agonists should still be 
considered experimental. In fact, members of ASCO Panel recommend that interested patients 
enrol onto clinical trials specifically designed to evaluate the effectiveness of fertility 
preservation by ovarian suppression methods, rather than receive off-study treatment.  
Other strategies under development include producing oocytes from stem cells and 
regenerating oocytes by inducing natural mechanisms.  
It is a central dogma of female reproductive biology that oogenesis ceases around the time 
of birth in mammalian species. In 2004, one study published by Johnson et al. (30), in which 
they claimed that in the adult mouse ovary, neo-oogenesis takes place and originates from 
female germline stem cells that are present in either the ovarian surface epithelium or bone 
marrow. Following these publications, experiments showed that non-germinal stem 
cells could generate oocytes. So at this moment there is a lot scientist trying to find the way 
to achieve oogenesis in adult mammals, but they are all experimental.  
3.1 Chemoprotection 
Preventing reproductive failure would be an ideal approach. Research is under way to 
evaluate treatment with gonadotropin-realising hormones (GnRh) in conjunction with 
chemotherapy, inducing a transient prepubertal state that might reduce the damage to 
reproductive organs and thereby prevent oocyte death during cancer treatment.  
However, fertility preservation using ovarian suppression with GnRh agonists should still 
be considered experimental. In fact, members of ASCO Panel recommend that interested 
patients enrol onto clinical trials specifically designed to evaluate the effectiveness of 
fertility preservation by ovarian suppression methods, rather than receive off-study 
treatment.  
Criticism of this approach is also derived from the fact that if the mechanism of action is 
primarily through hypothalamic pituitary suppression, this should not protect early follicle 
damage that is gonadotropin independent. However a direct gonadal effect is possible. 
At present, the data are unconvincing, with most findings derived from non-randomly 
controlled studies. There are, however, large studies under way which may yield definitive 
answers.  
Therapy with a variety of suppressive agents such as oral contraceptives or progestins has 
not been shown to be effective in preventing damage from chemotherapy or radiation 
therapy. 
3.2 Ovariopexy 
Moving the ovaries out of the field of irradiation can help maintain ovarian function in 
patients scheduled to undergo gonadotoxic radiotherapy. This significantly reduces ovarian 
radiation exposure in patients who receive pelvic irradiation such as those with Hodkin’s 
disease or genitourinary or low intestinal malignancies. For instance, the ovarian dose 
following transposition is reduced to approximately 5-10 percent of the in situ ovaries.  
Lateral transposition appears to be more effective than suturing the ovaries to the posterior 
face of the uterus. 
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The transposition is typically performed by laparotomy. This approach is used at the time of 
radical hysterectomy for cervical cancer. If there is no need of laparotomy for cancer 
excision, ovarian transposition should be performed laparoscopically just prior initiation of 
radiation therapy.    
3.3 Assisted reproductive technologies 
Assisted reproductive technology is probably the most used modality in patients that wish 
to proceed to fertility preservation. The American Society of Reproductive Medicine 
recognizes that there is sufficient evidence to recommend embryo cryopreservation as a 
routine clinical care compared with other therapeutic strategies. 
3.3.1 Oocyte cryopreservation 
Oocyte cryopreservation is an alternative to embryo storage and is ideal for women who do 
not have a partner and do not want to use donor sperm. For this procedure, the patient has 
to undergo ovarian stimulation and egg retrieval, the same process required for embryo 
cryopreservation. Oocyte cryopreservation does not require IVF or ICSI (IntraCitomasplatic 
Sperm Inyection), and creation of unnecessary embryos can be prevented. 
Although oocyte cryopreservation is still considered experimental in the United States, this 
technology has proven successful. Indeed, current live-birth rates from series of frozen-
thawed oocytes are comparable to those in frozen-thawed embryo cycles, and there was no 
apparent increase in the rate of congenital anomalies as compared with U.S. national 
statistics for natural conceptions as reported by the Centres for Disease Control. 
Actually there are two kind of techniques used for cryopreservation of oocytes: Vitrification 
and slow freezing.  
To date, there is no standard protocol for vitrification of oocytes, which makes an analysis of 
published data difficult. 
Since 2005, the pregnancy rates and live-birth rates have been significantly increased in both 
slow freezing and vitrification groups. (19). 
When the data from 1998–2008 is analyzed, oocyte survival rate was higher in the vitrified 
group (81%) compared with in the slow frozen group (68%). The live-birth rate per ET was 
14%and 34%in the slow frozen and vitrified group, respectively. 
Cryopreservation of immature oocytes at the stage of germinal vesicle (GV) can be an 
attractive alternative to cryopreservation of mature oocytes, especially in breast cancer patients 
(Figure 3). In theory, there are several advantages of GV stage oocyte cryopreservation. First of 
all, it does not require full ovarian stimulation, which can be a significant benefit for breast 
cancer patients who cannot delay cancer treatment or who have ERþ (estrogen-progestin 
receptors) tumor. It wills also benefit women who are at high risk for ovarian 
hyperstimulation syndrome such as patients with polycystic ovarian syndrome. (4) 
To date, cryopreservation of immature oocytes at the GV stage has not been very successful. 
Nevertheless, immature oocyte cryopreservation followed by in vitro maturation can be a 
powerful tool for fertility preservation in breast cancer patients.  
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Fig. 3. Examples of GV state above and mature oocyte below. 
3.3.2 Embryo cryopreservation 
Embryo storage is ideal for an adult woman in a stable relationship as it is an established 
technique which has been available since the mid 1980s. 
IVF and ICSI offer a success rate of approximately 30% per cycle (dependent on age) and this is 
similar to the natural conception rate that is achievable by healthy couples without assisted 
reproductive techniques. It involves stimulating the ovaries using gonadotrophins which 
results in high oestrogen levels, and certainly this raises concerns for some tumours such as 
breast cancers with oestrogen receptor positivity. It is still unclear what are the risks of such 
techniques in terms of tumour progression or relapse in a hormone dependent cancer. Some 
groups have attempted to address this by using tamoxifen or letrozole alone or in combination 
with standard IVF stimulation for women with breast cancer or endometrial cancer.  
Patient numbers are small and long-term studies are currently not available. There are also 
no data on the pregnancy outcome from embryos generated from these protocols. However, 
many women and their physicians will choose not to expose an estrogen-responsive cancer 
to more estrogenic stimulation than is strictly necessary. (4) 
IVF protocols are well defined, although it may be helpful under some circumstances to 
induce luteolysis with a GnRH antagonist to allow FSH injections to start sooner.  GnRH 
antagonists also allow for a shorter duration of treatment.   
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IVF stimulation takes a minimum of two to three weeks depending on a patient’s 
menstrual cycle and could be anything up to five weeks. After stimulation of follicles to 
maturation an egg collection procedure is undertaken usually as a day case under 
sedation or a general anaesthetic where vaginal ultrasound probe is used to guide 
transvaginal collection of eggs. IVF is then undertaken to fertilise the patient’s eggs with 
the partner’s sperm before freezing the embryo. At present there is limited availability 
donor sperm for adult women trying to preserve reproductive potential whilst 
undertaking chemotherapy (Figure 4). 
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F. 
A. Sperm selection for insemination into oocyte (ICSI technique) 
B. Sperm aspiration. 
C. Oocyte punction. 
D. Introducing the sperm into the oocyte cytoplasm. 
E. Fertilize oocyte at 2 pronuclear stage. 
F. Embryo at 72 hs after fertilization at 8 cells stage. 
Fig. 4. ICSI technique. 
3.3.3 Ovarian tissue cryopreservation 
An alternative option therefore is to store ovarian tissue, which may contain many more 
oocytes. Advantages include the fact that no other treatment is required and it can be carried 
out at short notice. It requires no male involvement, but does require a surgical procedure 
both to recover the tissue and replace it at a later date. 
Replacement provides the option of spontaneous rather than assisted conception as well as 
the chance of more than one pregnancy; this has now been demonstrated.(11)(13)  
Importantly, ovarian tissue cryopreservation also offers a potential option for children and 
adolescents for whom ovarian stimulation is inappropriate. This, however, may be better 
described as a theoretical option; as yet no adolescent girl has gone on to have a child 
following this procedure.   
One important consideration is that a significant amount of ovarian tissue must be removed 
from the patient and will not therefore be available for spontaneous fertility should she not 
be sterilised by her cancer treatment.   
At present there is debate over whether unilateral oophorectomy or ovarian biopsy is the 
more appropriate surgical technique. 
All human trials of cryopreserved autotransplanted tissue have been with cortical strips. 
This concept was developed from previous work in animal models that have used 
cryopreserved thawed ovarian cortical strips and reported follicular survival and endocrine 
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function as well as restoration of fertility after transplantation of cryopreserved-thawed 
ovarian cortical strips. Using present techniques, ovarian tissue strips are removed from the 
patient prior to chemotherapy. They are frozen in small strips  (Figure 5). When the patient 
is ready for pregnancy, they are transplanted back into the patient in a heterotopic or 
orthotopic site. Since this is an avascular graft, up to two-thirds of follicles are lost after 
transplantation. Given this limitation it has been recommended that ovarian tissue freezing 
should be restricted to patients younger than thirty five years. 
At present a total of 14 children have been born to women who have had ovarian tissue 
cryopreserved and reimplanted. Both spontaneous and assisted conceptions have been 
demonstrated, but interestingly no successful pregnancies have yet been described 
following heterotopic transplantation of the ovary. Sites where follicular growth has been 
observed include the anterior abdominal wall and the arm, although successful non-human 
primate pregnancies have been reported following fresh transplantation to a subcutaneous 
site. These approaches do, however, offer the opportunity for our improved understanding 
of the extra-ovarian requirements for normal follicular and oocyte development. 
 
Fig. 5. Ovarian tissue preparation for cryopreservation. 
The malignant contamination of the ovarian tissue must also be considered. So far, a total of 
some 30 women have received transplantation of ovarian tissue without any reports of 
relapse caused by the transplantation. Two large series of ovarian biopsies in breast cancer 
patients have recently revealed no evidence of malignant cell contamination, but the 
availability of specific molecular tumour markers in some conditions has revealed the 
potential for contamination. This is a particular issue for haematological malignancies; 
importantly, chemotherapy prior to ovarian cryopreservation did not preclude 
contamination. (12) 
There are several potential uses of cryopreserved ovarian tissue: transplantation back into 
the host, in vitro maduration of primordial follicles, and xenografting into a host animal. 
The tissue can be transplanted back into patient.  
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Research should focus on refining the cryopreservation protocols, cryoprotectants, and 
transplantation techniques that decrease ischemia, particularly the use of vascularised 
grafts. 
4. Facilitating fertility preservation consultation 
Treating physicians should initiate the discussion of the possible treatment-related effects to 
fertility and indicate that there are options to safeguard their future fertility potential. (20) 
Women of reproductive potential and interested in learning about options for fertility 
preservation should be referred real time to a reproductive endocrinologist. Preferably, a 
fertility preservation consultation should be arranged at the time of the initial diagnosis to 
expedite necessary options including COS and oocyte retrieval for embryo cryopreservation 
or alternative fertility preservation techniques. Using these referral mechanisms can 
eliminate time delays for appointments, initiate education on the process to the patient, and 
provide documentation such as pathology reports or treatment plans to the referring 
clinician. Without the development of such a streamlined process, patients and providers 
will experience frustration and unnecessary time delays. Nevertheless, many patients fail to 
pursue fertility preservation options owing to two main barriers, time and cost. Of note, 
most procedures for fertility preservation are not covered by insurance in many 
countries.(6) 
5. Conclusion 
So it’s fair to say that there have been substantial advances in fertility preservation in the last 
decade, but there still remain very significant gaps in our knowledge as to how best to 
proceed.  
Patient selection remains a challenge, to be confident in offering treatment to those who 
need it and reassuring to those who do not. In this respect we have recently shown that 
serum AMH (anti müllerian hormone) predicts long-term ovarian function following 
chemotherapy in women with breast cancer. Indeed, in a multivariate analysis only AMH, 
but not age or FSH, remained a significant predictor. 
This result, if confirmed, may allow a more individualised risk assessment based on the 
proposed treatment regime and a measure of the patient's ovarian reserve. 
Improved cancer care associated with increased cure rates and long-term survival, coupled 
with advances in fertility treatment means that it is now imperative that fertility 
preservation is considered as part of the care offered to these patients. This can only be 
approached within a multidisciplinary setting. There are obvious challenges that still remain 
to be resolved, especially in the area of fertility preservation in prepubertal patients. These 
include ethical issues, such as valid consent and research in the area of tissue retrieval, 
cryopreservation and transplantation. 
Long-term survival is expected in most women with cancer as a result of advances in cancer 
treatment. For young cancer survivors who have not completed their family, fertility is a 
crucial issue. Informed decision making regarding future fertility can lead to decreased 
patient regret and improved quality of life.  
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Use of less gonadotoxic regimens for adjuvant or neoadjuvant chemotherapy may be 
considered in young cancer patients with favourable tumors who are in their reproductive 
years. When there is a high risk of losing fertility with aggressive cancer treatment, currently 
available options for fertility preservation should be discussed. Embryo cryopreservation is 
a well-established technology and suitable for women who have a partner. Oocyte 
cryopreservation is an alternative option that can avoid ethical and legal issues (unlike 
embryo cryopreservation). However, neither embryo nor oocyte cryopreservation is a 
practical option for women who cannot delay cancer treatment. In addition, COS (Control 
Ovarian Stimulation) is required for both embryo and oocyte cryopreservation, and an 
increase in peak E2 levels with COS  may accelerate tumour growth in some types of  breast 
cancer with ERþ (estrogen-progestin receptors). The alternative COS strategy using 
tamoxifen or letrozole in conjunction with gonadotropin can suppress the elevation of E2 
levels and may be considered for women with ERþ tumour in breast cancer.  
Where embryo or oocyte cryopreservation is not indicated, cryopreservation of ovarian 
tissue can be a reasonable alternative, without the worry of delaying cancer treatment or 
increasing E2 levels. Fertility specialists should work closely with breast cancer treatment 
teams to provide options for fertility preservation before the initiation of cancer treatment in 
young women with breast cancer. A multidisciplinary program such as a breast cancer 
survivorship program will facilitate timely communications between oncologists and 
fertility specialists as well as effective transmission of information to health care providers 
and patients.(4) 
In addition to developing techniques for preserving or restoring fertility, researchers should 
consider the long-term effects of such technologies, such as egg quality, healthy pregnancies 
and, most important, healthy babies. 
The advisory panel also acknowledged the need to consider behavioural, cultural, religious, 
health disparities, ethical, legal and financial aspects of fertility preservation research.  
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